SRRK — Scholar Rock Holding Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1727196 ·
Last close
$42.20
Market Cap
$5.14B
52W High
$61.76
52W Low
$27.07
ADV30
2,012,015
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -108,901,000 | -109,896,000 | 523,543,000 | 437,091,000 | 269,759,000 |
| Mar 2026 | 0 | — | -102,016,000 | -105,510,000 | 535,254,000 | 430,543,000 | 259,241,000 |
| Dec 2025 | 0 | — | -91,896,000 | -90,965,000 | 404,272,000 | 323,527,000 | 158,784,000 |
| Sep 2025 | 0 | — | -103,550,000 | -102,220,000 | 411,718,000 | 286,770,000 | 166,723,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-296,827,000
Investing CF
$87,832,000
Financing CF
$494,660,000
CapEx
$-185,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.45
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,516,060,000
Inventory
—
Receivables
$1,959,000
ST Investments
$54,997,000
EBIT TTM
$-397,903,000
Pretax Income TTM
$-408,591,000
Interest Exp TTM
$10,688,000
Analysts
16
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -384,645,000 | -377,939,000 | 404,272,000 | 158,784,000 | 245,488,000 | -300,035,000 |
| Dec 2024 | 0 | -252,054,000 | -246,294,000 | 474,922,000 | 106,288,000 | 368,634,000 | -200,949,000 |
| Dec 2023 | 0 | -171,295,000 | -165,789,000 | 311,035,000 | 85,817,000 | 225,218,000 | -145,226,000 |
| Dec 2022 | 33,193,000 | -134,370,000 | -134,502,000 | 358,168,000 | 97,933,000 | 260,235,000 | -132,694,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-408,726,000
OpCashFlow TTM
—
Assets (Latest)
$535,254,000
Forward EPS
$-2.33
Max Pain — expiry 2026-10-16
max pain strike: $50.00 · spot: $42.19 · call oi: 3,649 · put oi: 1,649
Expected Move to 2026-10-16:
±$3.98
(9.42%) —
implied range
$38.21 –
$46.16
· ATM straddle on $40.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | $4.88B | $50.44 | — |
| CGON | CG Oncology, Inc. | $5.61B | $63.26 | — |
| KOD | Kodiak Sciences Inc. | $5.92B | $94.26 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $6.03B | $13.31 | — |
| IMVT | Immunovant, Inc. | $6.25B | $30.26 | — |
News headlines (Yahoo Finance, 1h cache)
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
2026-10-08 12:00 · Yahoo
3 drug targets pharma is betting on next
2026-10-02 13:00 · Yahoo
Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says
2026-09-25 16:35 · Yahoo
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-21 16:00 · Yahoo
This week in charts: GSK’s China deals, the $300M IPO club and selling the news
2026-09-18 10:43 · Yahoo
Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?
2026-09-17 04:06 · Yahoo
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions
2026-09-15 23:16 · Yahoo
Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says
2026-09-14 16:17 · Yahoo
Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular Atrophy
2026-09-14 12:08 · Yahoo
Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump
2026-09-14 11:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.